版本:
中国

BRIEF-Ocular and Regeneron enter into strategic collaboration to develop sustained release formulation of aflibercept

Oct 13 Ocular Therapeutix Inc :

* Ocular Therapeutix(tm) and Regeneron enter into strategic collaboration to develop sustained release formulation of aflibercept for the treatment of wet AMD and other serious retinal diseases

* Ocular Therapeutix Inc - eligible to receive up to $305 million in milestone payments in addition to royalties on potential future net sales Source text for Eikon: Further company coverage: ;))

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐